Dharmaprakash Akhilandeswarre, Thandavarayan Ramamurthy, Joseph Iype, Thomas Sabu
Cholera & Biofilm Research Laboratory, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram - 695 014, Kerala, India.
National Institute of Cholera & Enteric Diseases (NICED), Kolkata - 700010, India.
Future Microbiol. 2015;10(6):1035-48. doi: 10.2217/fmb.15.14.
The severity of many chronic bacterial infections is mainly due to the biofilm mode of life adapted by pathogenic bacteria. The bacteria in biofilm-stage exhibit high resistance to host immune responses and antimicrobials, which complicates the treatment process and results in life threatening conditions. Most of the chronic infections are polymicrobial in nature. In order to combat the polymicrobial biofilm infections and to increase the efficiency of antimicrobials, there is an urgent need for broad-spectrum antibiofilm drugs. This review discusses the clinical needs and current status of broad-spectrum antibiofilm drugs with special emphasis on prospective strategies and hurdles in the process of new drug discovery.
许多慢性细菌感染的严重程度主要归因于病原菌所采用的生物膜生活方式。处于生物膜阶段的细菌对宿主免疫反应和抗菌药物表现出高度抗性，这使治疗过程复杂化并导致危及生命的状况。大多数慢性感染本质上是多微生物感染。为了对抗多微生物生物膜感染并提高抗菌药物的效率，迫切需要广谱抗生物膜药物。本综述讨论了广谱抗生物膜药物的临床需求和现状，特别强调了新药发现过程中的前瞻性策略和障碍。
